Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tindara Franchina

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Forum (Genoa, Italy)|July 29, 2006
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative careVincenzo Adamo, Giuseppa Ferraro, Barbara Adamo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2016
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I MutationAlessandro Russo, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi, et al.
Oncotargets and Therapy|February 14, 2015
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastasesGiuseppina Rosaria Rita Ricciardi, Alessandro Russo, Tindara Franchina, et al.
International Journal of Molecular Sciences|March 24, 2019
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical ScenarioAlessandro Russo, Tindara Franchina, Giuseppina Ricciardi, et al.
Oncotargets and Therapy|August 9, 2016
Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancerGiuseppina Rosaria Rita Ricciardi, Tindara Franchina, Alessandro Russo, et al.
Frontiers in Endocrinology|June 6, 2012
Emerging targeted therapies for castration-resistant prostate cancerVincenzo Adamo, Laura Noto, Tindara Franchina, et al.
Cancer Biology & Therapy|September 10, 2016
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic siteTindara Franchina, Alessandro Russo, Giuseppina Rosaria Ricciardi, et al.
Cancers|January 8, 2023
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life ScenarioCalogera Claudia Spagnolo, Giuseppe Giuffrida, Salvatore Cannavò, et al.
BMC Cancer|January 27, 2018
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature reviewGiuseppina Rosaria Rita Ricciardi, Alessandro Russo, Tindara Franchina, et al.
Journal of Cellular Biochemistry|June 25, 2013
IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicitySebastiano Gangemi, Tindara Franchina, Paola Lucia Minciullo, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Forum (Genoa, Italy)|July 29, 2006
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative careVincenzo Adamo, Giuseppa Ferraro, Barbara Adamo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2016
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I MutationAlessandro Russo, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi, et al.
Oncotargets and Therapy|February 14, 2015
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastasesGiuseppina Rosaria Rita Ricciardi, Alessandro Russo, Tindara Franchina, et al.
International Journal of Molecular Sciences|March 24, 2019
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical ScenarioAlessandro Russo, Tindara Franchina, Giuseppina Ricciardi, et al.
Oncotargets and Therapy|August 9, 2016
Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancerGiuseppina Rosaria Rita Ricciardi, Tindara Franchina, Alessandro Russo, et al.
Frontiers in Endocrinology|June 6, 2012
Emerging targeted therapies for castration-resistant prostate cancerVincenzo Adamo, Laura Noto, Tindara Franchina, et al.
Cancer Biology & Therapy|September 10, 2016
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic siteTindara Franchina, Alessandro Russo, Giuseppina Rosaria Ricciardi, et al.
Cancers|January 8, 2023
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life ScenarioCalogera Claudia Spagnolo, Giuseppe Giuffrida, Salvatore Cannavò, et al.
BMC Cancer|January 27, 2018
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature reviewGiuseppina Rosaria Rita Ricciardi, Alessandro Russo, Tindara Franchina, et al.
Journal of Cellular Biochemistry|June 25, 2013
IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicitySebastiano Gangemi, Tindara Franchina, Paola Lucia Minciullo, et al.
Pageof 7